About Allist
Profile
Awards & Recognition
History
Science Advisory Broad
R & D
Pipeline
Manufacturing
Collaborations & Partnership
Products
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
English
中文
菜单
Search
Home
About Allist
Profile
Awards & Recognition
History
Science Advisory Broad
R & D
Pipeline
Manufacturing
Collaborations & Partnership
Products
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
English
News
Advancing Long Life with Innovation of Science and Technology
Archive
2023/10/30
Great New | Allist Annouces that FDA Grants Breakthrough Therapy Designation to Furmonertinib in First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2023/09/10
Spotlight for Furmonertinib – NSCLC with EGFR Exon 20 Insertions Data Public at 2023 WCLC
2023/04/04
Furmonertinib Received New Indication IND Approval by CDE – Comprehensive Cover, Global Synchronization
2023/03/02
Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)
2023/03/01
Allist Pharmaceuticals Annouced Today the Signing of a License Agreement with Abbisko Therapeutics for a New Generation of EGFR TKI, called ABK3376
2022/08/05
Furmonertinib Published in Prestigious International Journal Once Again
2022/08/04
Ivesa® won the "14th China Health Forum - Top 10 New Drugs (in China)”
2022/07/22
Allist listed on “TOP 100 Hardcore Technology Enterprises in Shanghai in 2022"
2022/06/29
Furmonertinib Approved for First-Line Treatment
2022/06/03
Furmonertinib Once Again Published in The Lancet Respiratory Medicine
共39记录
«上一页
1
2
3
4
下一页»